012 plans IPO in New York

The Petah Tikva-based company is offering 6.675 million shares at a range of between $14 to $16 each.

October 31, 2007 08:14


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user uxperience almost completely free of ads
  • Access to our Premium Section and our monthly magazine to learn Hebrew, Ivrit
  • Content from the award-winning Jerusalem Repor
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

012 Smile.Communications Ltd., a provider of broadband access and international calls, will sell as much as $122.8 million in shares in an initial public offering in New York this week. The Petah Tikva-based company is offering 6.675 million shares at a range of between $14 to $16 each and may sell as much as another one million if there is sufficient interest, it said in a Securities and Exchange Commission filing. 012 Smile is a subsidiary of Internet Gold-Golden Lines Ltd., whose stake in the company will fall to 73.3 percent after the sale. 012 Smile said in a filing this month it estimates having 34% of Israel's international call market and 32% of its broadband access. Underwriters of the sale include CIBC World Markets, RBC Capital Markets, Cowen & Co., Oppenheimer & Co., and Thomas Weisel Partners LLC.

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection